Weight gain is a frequent effect when using Megeis in patients with breast or endometrial cancer and is a consequence of increased appetite.
Thromboembolism. There have been reports of thromboembolism, including thrombophlebitis and pulmonary embolism.
Other side effects. Nausea, vomiting, swelling and blood discharge from the uterine cavity, not associated with menstruation, are noted in approximately 1-2% of patients. It has been reported that patients have shortness of breath, pain, heart failure, hypertension, hot flashes, mood changes, Cushingoid features on the face, temporary activation of tumor development (in the absence or presence of hypercalcemia), hyperglycemia, alopecia, carpal tunnel syndrome, diarrhea, lethargy, skin rashes.
It was reported on the development of pathological conditions associated with impaired functioning of the pituitary-adrenal system: glucose intolerance, the onset of diabetes mellitus and exacerbation of existing diabetes mellitus with a decrease in glucose tolerance and Cushing's syndrome. In rare cases, patients soon after discontinuing treatment with MEGAIS, clinical signs of adrenal insufficiency were observed. It should be borne in mind the possibility of suppressing the function of the adrenal glands in all patients taking the drug for a long time, as well as after discontinuing the drug. In such cases, shock doses of glucocorticoids may be indicated as a substitution therapy.